An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)
Sponsor: Boehringer Ingelheim
This PHASE3 trial investigates Carcinoma, Non-Small-Cell Lung and is currently completed. Boehringer Ingelheim leads this study, which shows 58 recorded versions since 2013 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
58 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
May 2025 — Sep 2025 [monthly]
Completed PHASE3
-
Sep 2024 — May 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Apr 2024 — Jul 2024 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
▶ Show 53 earlier versions
-
Feb 2024 — Apr 2024 [monthly]
Active Not Recruiting PHASE3
-
Jan 2024 — Feb 2024 [monthly]
Active Not Recruiting PHASE3
-
Aug 2023 — Jan 2024 [monthly]
Active Not Recruiting PHASE3
-
Jul 2023 — Aug 2023 [monthly]
Active Not Recruiting PHASE3
-
Jun 2023 — Jul 2023 [monthly]
Active Not Recruiting PHASE3
-
May 2023 — Jun 2023 [monthly]
Active Not Recruiting PHASE3
-
Apr 2023 — May 2023 [monthly]
Active Not Recruiting PHASE3
-
Mar 2023 — Apr 2023 [monthly]
Active Not Recruiting PHASE3
-
Feb 2023 — Mar 2023 [monthly]
Active Not Recruiting PHASE3
-
Jan 2023 — Feb 2023 [monthly]
Active Not Recruiting PHASE3
-
Dec 2022 — Jan 2023 [monthly]
Active Not Recruiting PHASE3
-
Nov 2022 — Dec 2022 [monthly]
Active Not Recruiting PHASE3
-
Sep 2022 — Nov 2022 [monthly]
Active Not Recruiting PHASE3
-
Jul 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE3
-
Jun 2022 — Jul 2022 [monthly]
Active Not Recruiting PHASE3
-
May 2022 — Jun 2022 [monthly]
Active Not Recruiting PHASE3
-
Apr 2022 — May 2022 [monthly]
Active Not Recruiting PHASE3
-
Mar 2022 — Apr 2022 [monthly]
Active Not Recruiting PHASE3
-
Feb 2022 — Mar 2022 [monthly]
Active Not Recruiting PHASE3
-
Jan 2022 — Feb 2022 [monthly]
Active Not Recruiting PHASE3
-
Dec 2021 — Jan 2022 [monthly]
Active Not Recruiting PHASE3
-
Nov 2021 — Dec 2021 [monthly]
Active Not Recruiting PHASE3
-
Oct 2021 — Nov 2021 [monthly]
Active Not Recruiting PHASE3
-
Sep 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE3
-
Jun 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE3
-
May 2021 — Jun 2021 [monthly]
Active Not Recruiting PHASE3
-
Apr 2021 — May 2021 [monthly]
Active Not Recruiting PHASE3
-
Mar 2021 — Apr 2021 [monthly]
Active Not Recruiting PHASE3
-
Feb 2021 — Mar 2021 [monthly]
Active Not Recruiting PHASE3
-
Jan 2021 — Feb 2021 [monthly]
Active Not Recruiting PHASE3
-
Dec 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
-
Nov 2020 — Dec 2020 [monthly]
Active Not Recruiting PHASE3
-
Oct 2020 — Nov 2020 [monthly]
Active Not Recruiting PHASE3
-
Sep 2020 — Oct 2020 [monthly]
Active Not Recruiting PHASE3
-
Aug 2020 — Sep 2020 [monthly]
Active Not Recruiting PHASE3
-
Jul 2020 — Aug 2020 [monthly]
Active Not Recruiting PHASE3
-
Jun 2020 — Jul 2020 [monthly]
Active Not Recruiting PHASE3
-
May 2020 — Jun 2020 [monthly]
Active Not Recruiting PHASE3
-
Apr 2020 — May 2020 [monthly]
Active Not Recruiting PHASE3
-
Mar 2020 — Apr 2020 [monthly]
Active Not Recruiting PHASE3
-
Dec 2019 — Mar 2020 [monthly]
Active Not Recruiting PHASE3
-
Oct 2019 — Dec 2019 [monthly]
Active Not Recruiting PHASE3
-
Aug 2019 — Oct 2019 [monthly]
Active Not Recruiting PHASE3
-
Jun 2019 — Aug 2019 [monthly]
Active Not Recruiting PHASE3
-
May 2019 — Jun 2019 [monthly]
Active Not Recruiting PHASE3
-
Feb 2019 — May 2019 [monthly]
Active Not Recruiting PHASE3
-
Dec 2018 — Feb 2019 [monthly]
Active Not Recruiting PHASE3
-
Sep 2018 — Dec 2018 [monthly]
Active Not Recruiting PHASE3
-
Jun 2018 — Sep 2018 [monthly]
Active Not Recruiting PHASE3
-
Dec 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
-
Oct 2017 — Dec 2017 [monthly]
Active Not Recruiting PHASE3
-
Aug 2017 — Oct 2017 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Aug 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Jul 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Boehringer Ingelheim
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
A Coruña, Spain , AT Albans, Australia , Alessandria, Italy , Alicante, Spain , Ancona, Italy , Athens, Greece , Avellino, Italy , Aviano (PN), Italy , Badalona, Spain , Barakaldo (Bilbao), Spain and 81 more locations